Editorial Commentary
REBECA trial: a new piece of the evidence for bevacizumab in platinum-resistant recurrent ovarian cancer
Abstract
Lee et al. (1) evaluated the efficacy and safety of bevacizumab in combination with single-agent chemotherapy for platinum-resistant ovarian cancer in a large retrospective analysis involving Korean women with platinum-resistant recurrent ovarian cancer from 27 different institutions.
